KIR3DL1 and cancer: Patients with both types of cancer exhibited higher numbers of NK cells expressing KIR2DL2 and KIR3DL1 compared to healthy controls, in both KIR2DL5+ individuals (KIR2DL2+ NK cells: 9.5% ± 1.5% and 8.3% ± 1.3% vs. 6.5% ± 1.1, p > 0.05; KIR3DL1+ NK cells: 19.8% ± 1.4% and 18.5% ± 1.3% vs. 14.9% ± 1.1, p < 0.05) and KIR2DL5− individuals (KIR2DL2+ NK cells: 17.4% ± 1.3% and 14.6% ± 1.5% vs. 12.5% ± 1.2, p < 0.05; KIR3DL1+ NK cells: 12.6% ± 1.2% and 11.3% ± 1.0% vs. 8.6% ± 0.7, p < 0.01).